mTOR as a potential treatment target for epilepsy

Future Neurology

Volumn 7, Issue 5, 2012, Pages 537-545

  Wong, Michael ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

epilepsy; rapamycin; seizure; tuberous sclerosis

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHENYTOIN; RAPAMYCIN; VALPROIC ACID;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; BRAIN INJURY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TARGETING; EPILEPTIC STATE; EPILEPTOGENESIS; HUMAN; NERVE CELL PLASTICITY; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEIZURE; TUBEROUS SCLEROSIS;

EID: 84866313862     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.12.45     Document Type: Article

References (58)

1. Kwan P, Brodie MJ. Refractory epilepsy: Mechanisms and solutions. Expert Rev. Neurother. 6, 397-406 (2006
2. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: Meta-analysis of controlled trials. Epilepsia 42, 515-524 (2001 (Pubitemid 32322197)
3. Pitkanen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 10, 173-186 (2011
4. Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. Epilepsia 51, 27-36 (2010
5. McDaniel SS, Wong M. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci. Lett. 497, 231-239 (2011
6. Galanopoulou AS, Gorter JA, Cepeda C. Finding a better drug for epilepsy: The mTOR pathway as an antiepileptogenic target. Epilepsia 53(7), 1119-1130 (2012
7. Cho CH. Frontier of epilepsy research - mTOR signaling pathway. Exp. Mol. Med. 43, 231-274 (2011
8. Zoncu R.,Efevan A.,Sabitini D.M. mTOR: From growth signal integration toZoncu R, Efevan A, Sabitini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell. Biol. 12, 21-35 (2011
9. Weber JD, Gutmann DH. Deconvoluting mTOR biology. Cell Cycle 11, 236-248 (2012
10. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibitors mTORC2 assembly and Akt/PBK. Mol. Cell 22, 159-169 (2006
11. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann. NY Acad. Sci. 1184, 87-105 (2010
12. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345-1356 (2006
13. Franz DN, Leonard J, Tudor C et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490-498 (2006 (Pubitemid 43358069)
14. Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811 (2010
15. Bissler JJ, McCormack FX, Young LR et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140-151 (2008
16. Dabora SL, Franz DN, Ashwal S et al. Multicenter Phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS ONE 6, e23379 (2011
17. Daoud D, Scheld HH, Speckmann EJ, Gorji A. Rapamycin: brain excitability studied in vitro. Epilepsia 48, 834-836 (2007 (Pubitemid 46587621)
18. Ruegg S, Baybis M, Juul H, Dichter M, Crino PB. Effects of rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons. Epilepsy Res. 77, 85-92 (2007 (Pubitemid 350137689)
19. Graham KF, Haddick PC, Jan YN, Jan LY. Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites. Science 314, 144-148 (2006 (Pubitemid 44547761)
20. Wang Y, Barbaro MF, Baraban SC. A role for the mTOR pathway in surface expression of AMPA receptors. Neurosci. Lett. 401, 35-39 (2006
21. Zeng L, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 63, 444-453 (2008 (Pubitemid 351614710)
22. Kwon C, Zhu X, Zhang J, Baker SJ. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl Acad. Sci. USA 100, 12923-12928 (2003 (Pubitemid 37340001)
23. Ljungberg MC, Sunnen CN, Lugo JN, Anderson AE, D'Arcangelo G. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia. Dis. Model. Mech. 2, 389-398 (2009
24. Sunnen CN, Brewster AL, Lugo JN et al. Inhibition of the mammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia 52, 2065-2075 (2011
25. Zhou J, Blundell J, Ogawa S et al. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J. Neurosci. 29, 1773-1783 (2009
26. Muncy J, Butler IJ, Koenig M. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J. Child Neurol. 24, 477 (2009
27. Perek-Poinik M, Jozwiak S, Jurkiewicz E, Perek D, Kotulska K. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex. Eur. J. Paediatr. Neurol. 16, 83-85 (2012
28. Wilfong A, Krueger DA, Holland-Bouley K et al. Everolimus improves seizure control in tuberous sclerosis complex. Presesent at: American Epilepsy Society Annual Meeting Baltimore, MD, USA, 2-6 December 2011 (Late-breaking Abstract 3.329
29. Huang X, Zhang H, Yang J et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol. Dis. 40, 193-199 (2010
30. Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulo AS. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol. Dis. 43, 322-328 (2011
31. Hartman A, Santos P, Hardwick JM. Rapamycin has anticonvulsant effects in acute seizure tests. Epilepsy Curr. 12 (Suppl. 1), S104 (2012
32. Huang X, McMahon J, Yang J, Shin D, Huang Y. Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats. Neuroscience 219, 33-47 (2012
33. Meikle L, Pollizzi K, Egnor A et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 28, 5422-5432 (2008
34. Goto J, Talos DM, Klein P et al. Regulable neural progenitor-specific TSC1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc. Natl Acad. Sci. USA 108, 1070-1079 (2011
35. Zeng L, Rensing NR, Zhang B, Gutmann DH, Gambello MJ, Wong M. TSC2 gene inactivation causes a more severe epilepsy phenotype than TSC1 inactivation in a mouse model of tuberous sclerosis complex. Hum. Mol. Genet. 20, 445-454 (2011
36. Carson RP, Van Nielen DL, Winzenburger PA, Ess KC. Neuronal and glia abnormalities in TSC1-deficient forebrain and partial rescue by rapamycin. Neurobiol. Dis. 45, 369-380 (2012
37. Buckmaster PS, Ingram EA, Wen X. Inhibition of the mammalian target of rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy. J. Neurosci. 29, 8259-8269 (2009
38. Tang H, Long H, Zeng C et al. Rapamycin suppresses the recurrent excitatory circuits of dentate gyrus in a mouse model of temporal lobe epilepsy. Biochem. Biophys. Res. Commun. 420, 199-204 (2012
39. Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci. 29, 6964-6972 (2009
40. van Vliet EA, Forte G, Holtman L et al. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. Epilepsia 53(7),1254-1263 (2012
41. Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol. Dis. 26, 86-93 (2007 (Pubitemid 46436489)
42. Talos DM, Sun H, Zhou X et al. The interaction between early life epilepsy and autistic-like behavioral consequences: A role for the mammalian target of rapamycin (mTORC1) pathway. PLoS ONE 7, e35885 (2012
43. Huang X, McMahon J, Huang Y. Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy. Neuroscience 215, 90-97 (2012
44. Buckmaster PS, Lew FH. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J. Neurosci. 31, 2337-2347 (2011
45. Sliwa A, Plucinska G, Bednarczyk J, Lukasiuk K. Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci. Lett. 509(2), 105-109 (2012
46. Chachua T, Yum MS, Veliskova J, Velisek L. Validation of the rat model of cryptogenic infantile spasms. Epilepsia 52, 1666-1677 (2011
47. Lew FH, Buckmaster PS. Is there a critical period for mossy fiber sprouting in a mouse model of temporal lobe epilepsy? Epilepsia 52, 2326-2332 (2011
48. Sosunov AA, Wu X, McGovern RA et al. The mTOR pathway is activated in glial cells in mesial temporal sclerosis. Epilepsia 53(Suppl. 1), S78-S86 (2012
49. Datta AN, Hahn CD, Sahin M. Clinical presentation and diagnosis of tuberous sclerosis complex in infancy. J. Child Neurol. 23, 268-273 (2008 (Pubitemid 351247618)
50. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51, 1236-1241 (2010
51. Jaworski J, Sheng M. The growing role of mTOR in neuronal development and plasticity. Mol. Neurobiol. 34, 205-219 (2012
52. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64, 252-261 (2004 (Pubitemid 38114106)
53. Woodrum C, Nobil A, Dabora SL. Comparison of three rapamycin dosing schedules in A/J Tsc2+/-mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J. Transl. Med. 8, 14 (2010
54. Rivera VM, Squillace RM, Miller D et al. Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol. Cancer Ther. 10, 1059-1071 (2011
55. Dazert E, Hall MN. mTOR signaling in disease. Curr. Opin. Cell Biol. 23, 744-755 (2011
56. Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K. Mammalian target of rapamycin: Hitting the bull's-eye for neurological disorders. Oxid. Med. Cell Longev. 3, 374-391 (2010
57. Bove J, Martinez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: Mechanistic insights. Nat. Rev. Neurosci. 12, 437-452 (2011
58. Ryther CC & Wong M. Mammalian target of rapamycin (mTOR) inhibition: Potential for antiseizure, antiepileptogenic, and epileptostatic therapy. Curr. Neurol. Neurosci. Rep. 12(4), 410-418 (2012